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BACKGROUND: Because of the recent grade C draft recommendation by the US Preventive Services Task Force (USPSTF) for pros-
tate cancer screening between the ages of 55 and 69 years, there is a need to determine whether this could be cost-effective in a US
population setting. METHODS: This study used a microsimulation model of screening and active surveillance (AS), based on data
from the European Randomized Study of Screening for Prostate Cancer and the Surveillance, Epidemiology, and End Results Pro-
gram, for the natural history of prostate cancer and Johns Hopkins AS cohort data to inform the probabilities of referral to treatment
during AS. A cohort of 10 million men, based on US life tables, was simulated. The lifetime costs and effects of screening between the
ages of 55 and 69 years with different screening frequencies and AS protocols were projected, and their cost-effectiveness was
determined. RESULTS: Quadrennial screening between the ages of 55 and 69 years (55, 59, 63, and 67 years) with AS for men with
low-risk cancers (ie, those with a Gleason score of 6 or lower) and yearly biopsies or triennial biopsies resulted in an incremental cost
per quality-adjusted life-year (QALY) of $51,918 or $69,380, respectively. Most policies in which screening was followed by immediate
treatment were dominated. In most sensitivity analyses, this study found a policy with which the cost per QALY remained below
$100,000. CONCLUSIONS: Prostate-specific antigen–based prostate cancer screening in the United States between the ages of 55
and 69 years, as recommended by the USPSTF, may be cost-effective at a $100,000 threshold but only with a quadrennial screening
frequency and with AS offered to all low-risk men. Cancer 2018;124:507-13. VC 2017 American Cancer Society.
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INTRODUCTION
Frequent prostate-specific antigen (PSA)–based screening in the United States has led to concerns that a substantial pro-
portion of screen-detected men may be overdiagnosed and overtreated. These concerns led the US Preventive Services
Task Force (USPSTF) to recommend against prostate cancer screening in 2012.1 In 2017, the USPSTF issued a draft
statement recommending shared decision making between the ages of 55 and 69 years.2 This in part due to the emergence
of active surveillance (AS) as the main option for treating low-risk, screen-detected men in the United States.3,4
However, this recommendation leaves many open questions, including whether prostate cancer screening combined
with immediate treatment or AS can be cost-effective, how frequently men should be screened between the ages of 55 and
69 years, and how AS should be performed after screen detection.
Most previous modeling efforts in prostate cancer screening5-13 have not included either the quality of life or the
costs or have not modeled AS. Heijnsdijk et al5 simulated many screening policies for the Netherlands and suggested that
only very limited screening (stopping at the age of 59 years) could be cost-effective, but explicit modeling of AS was not
included. Previous studies that have modeled delayed treatment or AS suggest that AS is safe,6,7 is less costly,8-10 and may
substantially reduce overtreatment.6,7 One recent study compared the cost-effectiveness of delayed treatment and immedi-
ate treatment and found that screening with conservative management may be cost-effective.11 However, that study did
not fully model AS and did not consider the role of different AS protocols.
In this study, we present estimates of the cost-effectiveness of screening policies based on the USPSTF draft state-
ment in combination with immediate treatment for all men or AS for low-risk (Gleason score of 6) and/or intermediate-
risk men (Gleason score of 31 4 or lower).
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MISCAN is a microsimulation model designed to evaluate
the effects of prostate cancer screening. A detailed descrip-
tion is available at http://cisnet.cancer.gov/prostate/profiles.
html and in previously published studies.7,13-15
The natural history model contained 18 health states
corresponding to the combinations of 3 stages (T1, T2, and
T3), 3 grades (Gleason score< 7, Gleason score of 7, and
Gleason score> 7), and the cancer’s metastasis status (yes or
no). Additional states were created to model AS. Men at
stage T2 with a Gleason score of 6 were classified as T2a or
T2bc, and men with a Gleason score of 7 were classified as
31 4 or 41 3 according to their remaining lead time and
age group. Initially, natural history parameters, which
included the onset of the disease, durations, and transition
probabilities between health states, were calibrated to
observed European Randomized Study of Screening for
Prostate Cancer (ERSPC) incidence data. This model was
adapted to the US situation by the addition of an extra haz-
ard of clinical diagnosis and by the acquisition of United
States–specific estimates for other parameters from Surveil-
lance, Epidemiology, and End Results (SEER) data.
The prostate cancer survival without treatment was
assigned at clinical detection and depended on the Gleason
score. It was estimated on the basis of SEER data from the
pre-PSA era (1983-1986). To correct for improvements in
survival not directly associated with screening or primary
treatment, we added a hazard ratio of 0.82 for prostate can-
cer survival, which was calibrated to the observed prostate
cancer mortality in the ERSPC control (no-screening)
group.7
In case the patient was screen-detected and referred
to AS, natural history progressed as if he had not been
screen-detected. A patient might exit AS because of
Gleason or volume progression (which it was assumed
could occur only after an increase in stage) in each biopsy
round, because of personal preference, or if he would be
clinically detected at the time. The probabilities of referral
to radical treatment were estimated on the basis of Johns
Hopkins AS observed treatment-free survival data, with
the rate of disease progression based on our natural history
model.16 For intermediate-risk men, we assumed that the
probabilities of referral to treatment, given progression,
were similar to those for low-risk men (Table 1 and Sup-
porting Table 1 [see online supporting information]).
The hazard ratios for prostate cancer survival after
radical treatment were 0.56 for radical prostatectomy
according to Bill-Axelson et al17 and 0.63 for radiation
therapy (when we maintained the same ratio of benefit
between radical prostatectomy and radiation therapy
from Etzioni et al18). The effect of screening was depen-
dent on the remaining lead time for nonmetastatic cases:
Cure probability5expðCure parameter3Lead timeÞ
The cure parameter was calibrated to the observed pros-
tate cancer mortality reduction in the ERSPC trial after
11 years of follow-up and equaled20.22.7
Screening and AS protocols
We simulated several cohorts by year of birth and on the
basis of US life tables for a total of 10 million men. The
age distribution of the sampled men was selected to match
the observed age distribution in the United States during
1973-2005. According to the new USPSTF draft recom-
mendation, men were screened between the ages of 55
and 69 years with different screening frequencies. Atten-
dance was assumed to be 90%, the PSA threshold for
biopsy referral was 4 ng/ml, and biopsy compliance was
TABLE 1. Modeling Referrals to Treatment in Active Surveillance
Event Modeling Parameter
Volume progression Indirectly modeled; may occur if, in the absence of
screening, there would be an increase in the T stage
Probability of volume progression given an
increase in the T stage
Gleason upgrade Directly modeled; may occur if, in the absence of
screening, the Gleason score would increase
Sensitivity for a Gleason upgrade
Clinical diagnosisa Time of clinical detection in the absence of screening Hazard of clinical diagnosis per stage
Referral to treatment in the
absence of progression
Randomly selected from all men in active surveillance Probability of treatment in the absence of evidence
of progression or clinical diagnosis
The parameters of the natural history model are calibrated to data from the European Randomized Study of Screening for Prostate Cancer and the Surveil-
lance, Epidemiology, and End Results Program.7,13,14 The parameters related to referral to treatment during active surveillance are calibrated to Johns Hopkins
active-surveillance cohort data,16 including the number of men experiencing volume progression or a Gleason upgrade, the number of men treated without evi-
dence of progression, and the 5-year treatment-free survival (Supporting Table 1 [see online supporting information]). If referred to treatment, patients are
equally distributed between radiation therapy and radical prostatectomy.
a For the clinical diagnosis event, all the related parameters are calibrated to Surveillance, Epidemiology, and End Results data and denote an additional haz-
ard of clinical detection in the United States in comparison with the European situation.
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equal to 41% on the basis of the Prostate, Lung, Colorec-
tal, and Ovarian Cancer Screening Trial (PLCO).19
After detection, we simulated several treatment path-
ways. We compared the immediate treatment situation
with the assignment of low-risk men (stage T2a, Gleason
score of 6, and PSA level< 10 ng/ml) to AS followed by
yearly biopsies. Other AS protocols also included
intermediate-risk men or a triennial interval between biop-
sies after the first year. We assumed that all men classified
as low-risk were selected for AS. The biopsy compliance
during AS was based on Prostate Cancer Research Interna-
tional: Active Surveillance–observed biopsy compliance20
(Supporting Table 2 [see online supporting information]).
Quality of Life and Costs
Quality-adjusted life-years (QALYs) were calculated with
utility estimates ranging from 0 (death or worst imagin-
able health) to 1 (full health). Utility estimates and dura-
tions concerning all stages of early detection and
treatment were similar to those of Heijnsdijk et al.21 We
assumed 1 week of utility loss (0.99) due to screening
attendance and 3 weeks due to biopsy (0.90). We divided
posttreatment utility loss into 3 phases (<2 months, 2-12
months, and 1-9 years). In particular, the utility for the
postrecovery period from radical treatment (1-9 years)
was calculated on the basis of Stewart et al22 and Sanda
et al23 (Supporting Table 3 [see online supporting infor-
mation]). During AS, utility loss could occur because of
repeat biopsies. The costs of screening were based on
Hayes et al.24 The cost of immediate treatment was an
estimate from another simulation model25 and included
posttreatment surveillance costs. Costs of palliative ther-
apy were based on Yabroff et al.26 Costs did not include
indirect costs (except in a sensitivity analysis; Table 2).
Outcomes
We estimated the cost-effectiveness of each AS protocol
and immediate treatment. The main outcome was the
incremental cost-effectiveness ratio. The average cost per
QALY gained was relative to the situation with no screen-
ing, and it was assumed that every clinically detected man
was treated immediately. We also showed cancers diag-
nosed and overdiagnosed, prostate cancer mortality and
life-years, and the overall cost of the screening program.
Sensitivity Analyses
To assess the effect of uncertainty around the parameter
estimates on the outcomes, several multivariate sensitivity
analyses were performed; they included the utility and
cost estimates for each event, the parameters of the model
related to the treatment benefit and referral to treatment
during AS, the benefit due to early detection, and the
effect of discounting (Table 3).
RESULTS
Effects
In Table 4, the effects of yearly screening followed by
immediate radical treatment or AS are shown. One hun-
dred fifty-eight cancers per 1000 screened men were diag-
nosed, and 53 were screen-detected; this resulted in 23
overdiagnosed cancers and in prostate cancer mortality
reductions of 23% and 21% for immediate treatment and
AS, respectively. We estimated, at a 3% discount rate, that
30 life-years were saved by screening, but with an adjust-
ment for the quality of life, this number was reduced to 17
(see Supporting Table 4 for the undiscounted values [see
online supporting information]).
With all low-risk patients referred to AS, the life-
years gained were reduced to 28; however, QALYs
increased to 18. Selecting intermediate-risk men for AS
resulted in 16 QALYs gained.
Reducing the frequency of screening to every 2 years
resulted in approximately 14 to 15 QALYs gained,
depending on the AS protocol; 10 to 11 QALYs were
gained with quadrennial screening.
Costs
The costs of screening yearly and treatment between the
ages of 55 and 69 years, with respect to the no-screening
TABLE 2. Utilities, Durations, and Costs of Screening
and Treatment
Event Utility Duration, y Cost, US $
Screening 0.99 0.02 151
Biopsy 0.90 0.06 743
Cancer diagnosis 0.80 0.08 —
RT,< 2 mo 0.73 0.16 23,565a
RT, 2-12 mo 0.78 0.84
RP,< 2 mo 0.67 0.16 16,946a
RP, 2-12 mo 0.77 0.84
AS (surveillance costs)b — 6 245/y
Postrecovery 0.95c 9
Palliative therapy 0.60 2.5 48,472d
Terminal illness 0.40 0.5
Abbreviations: AS, active surveillance; RP, radical prostatectomy; RT, radia-
tion therapy.
All utilities and durations are based on Heijnsdijk et al.21 The costs of
screening are based on Hayes et al.24
a The costs of RP and RT include surveillance costs.25
b The surveillance costs of AS include 4 prostate-specific antigen tests and
1 visit to the physician per year for 6 years. These costs do not yet include
the cost of biopsy because this depends on the AS protocol.
c Based on data from Stewart et al22 and Sanda et al.23 For the calculation,
see Supporting Table 3 (see online supporting information).
d Based on Yabroff et al.26
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situation, were approximately $1.8 million for immediate
treatment for 1000 screened men and $1.7 million for AS
with yearly biopsies. When we reduced the frequency to
every 2 or 4 years, the costs become $1.0 million or $0.6
million per 1000 screened men, respectively.
Average Cost per QALY
The costs per QALY gained of screening men yearly
between the ages of 55 and 69 years and treating every man
immediately were approximately $103,037. When low-
risk men were referred to AS with yearly or 3-year biopsies,
this cost was reduced to $91,979 or $91,654, respectively.
Screening every 2 or 4 years resulted in a cost per QALY of
$73,590 or $55,673, respectively.
Incremental Cost-Effectiveness
Of all the screening and AS policies considered, we deter-
mined which were the most efficient according to their
incremental cost-effectiveness. Most policies in which
screening was followed by immediate treatment or in
which screening was followed by AS for low- and
intermediate-risk men were dominated; that is, they were
more expensive and resulted in fewer QALYs gained.
Screening between the ages of 55 and 69 years every
4 years (at the ages of 55, 59, 63, and 67 years) and offer-
ing AS to low-risk men with yearly or triennial biopsies
resulted in an incremental cost per QALY lower than the
$100,000 threshold.
Multivariate Sensitivity Analyses
In the multivariate sensitivity analyses, we focused on
screening between the ages of 55 and 69 years every 4
years. When the set of unfavorable utilities was used, the
(incremental) cost per QALY significantly increased in all
cases, and AS with yearly biopsies, which was efficient in
the base case, became dominated. With the set of favor-
able utilities, immediate treatment dominated the other
alternatives (Supporting Table 5 [see online supporting
information] and Fig. 1). Computing the cost-
effectiveness with a 6% discount rate resulted in a situa-
tion in which no policy had a cost per QALY lower than
$100,000. If there was no discounting, AS would lose its
advantage, and immediate treatment would become cost-
effective (Supporting Table 5 and Fig. 1).
We also varied several sets of model parameters. In
all situations, immediate radical treatment and AS for
low- and intermediate-risk men remained dominated. In
particular, a lower hazard ratio for treatment and baseline
survival (more lives saved by treatment) resulted in a
higher cost per QALY in all cases. Varying the probabili-
ties of referral from AS to immediate treatment had a low
impact on the cost per QALY of AS (Supporting Table 6
[see online supporting information] and Fig. 1).
DISCUSSION
In this study, we estimated the costs and effects associated
with screening followed by AS or immediate treatment in
comparison with no screening in the US population. We
found that between the ages of 55 and 69 years, only qua-
drennial screening (55, 59, 63, and 67 years) with AS for
low-risk men could be cost-effective at a $100,000 thresh-
old. Strategies in which immediate treatment is offered to
all men are dominated by strategies in which AS is offered
to low-risk men; that is, AS results in more QALYs gained
and lower costs than immediate treatment.
Our findings are consistent with those of Heijnsdijk
et al,5 who found that only very limited screening can be
cost-effective, and Roth et al,11 who found that screening
TABLE 3. Overview of Included Uncertainty in the
Multivariate Sensitivity Analyses
Parameters Value Range
Cure parameter 20.22 220% to1 20%
Hazard ratios for treatment and
baseline survival
Hazard ratio of improvement in
baseline survival
0.82 220% to1 20%
Hazard ratio of RP 0.56 0.41-0.77a
Hazard ratio of RT 0.63 0.46-0.87a
Active-surveillance parameters
Sensitivity to Gleason progression 0.4 220% to1 20%
Probability of detection of volume
upgrade (T2a)
0.1 220% to1 20%
Probability of detection of volume
upgrade (>T2a)
0.5 220% to1 20%
Probability of referral to treatment
without progression




Cancer diagnosis 0.80 0.85-0.75
RT,< 2 mo 0.73 0.75-0.71
RT, 2-12 mo 0.78 0.88-0.68
RP,< 2 mo 0.67 0.78-0.56
RP, 2-12 mo 0.77 0.84-0.70
Postrecovery 0.95c 0.93-0.97
Palliative therapy 0.60 0.24-0.86
Terminal illness 0.40 0.24-0.56
Abbreviations: RP, radical prostatectomy; RT, radiation therapy.
In 2 additional separate analyses, all costs were varied by 50% more and
less, and the cost-effectiveness was recalculated with 0% and 6%
discounts.
a The confidence interval for the hazard ratio is shown. The confidence
interval for RP was taken from Bill-Axelson et al.17 The confidence interval
for RT was extrapolated with the same ratio used by Etzioni et al.18
b Adapted from Heijnsdijk et al.5 Favorable/unfavorable refers to whether
the utility gives more/fewer quality-adjusted life-years gained by screening,
respectively.
c Based on Heijnsdijk et al,5 Stewart et al,22 and Sanda et al.23 For details,
see Supporting Table 3 (see online supporting information).
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with conservative management is more cost-effective than
screening with immediate treatment. In addition, previ-
ous studies of AS have shown that it has the potential to
significantly reduce the harms of prostate cancer screening
while keeping a large portion of the benefit.6-11
Our sensitivity analyses show that these findings are
robust to changes in the most important model parameters,
utilities and costs, although the most efficient screening and
AS protocol may change. The only scenarios in which AS
would lose its advantage in comparison with immediate
treatment would occur if we did not use discounting or if
we used the set of more favorable utilities toward screening
and treatment. Screening every 4 years with AS may result
in an incremental cost per QALY higher than $100,000 if
we were to increase the discount rate to 6%.
Our study links the cost-effectiveness of screening
between the ages of 55 and 69 years with different AS pro-
tocols. Furthermore, our model has a natural history of
prostate cancer in which all transition probabilities
between the different disease stages were calibrated to the
observed incidence in a large randomized control trial
(ERSPC).27 We adapted this to the US context by adding
US life tables and US screening patterns and by adapting
the rate of clinical diagnosis and sensitivity to match the
observed incidence of prostate cancer in the United States
with SEER data. The probabilities of referral to treatment
during AS were estimated on the basis of the observed
treatment-free survival in the Johns Hopkins cohort.16 In
contrast to Roth et al,11 we modeled AS explicitly.
The results of this study are also subject to some lim-
itations. The costs of treatment were obtained from the
lifetime estimates from another microsimulation model,25
and they do not include the costs of salvage treatment. We
found that the utility estimates have a significant effect on
the cost per QALY. In particular, the results are sensitive
to the utility of treatment postrecovery because it has a
duration of 9 years by assumption.
We considered screening only within the age group
of 55 to 69 years; however, previous studies have sug-
gested that lowering the stopping age may significantly
reduce overdiagnosis,5,12,13 and a recent study has found
that PSA screening between the ages of 50 and 55 years
could also be beneficial.28 Therefore, screening in this age
group is likely not optimal.
Our AS model uses a simplification of the actual cri-
teria for selection and later referral to treatment. For
instance, although our model uses the PSA, T stage, and
Gleason score as selection criteria, most AS cohorts also
use the number of positive biopsy cores or PSA density.29
The probabilities of referral to treatment during AS are





















AS, 3 y 11 14.6 10.3 0.54 51,918 51,918
AS, intermediate 10 13.6 9.6 0.55 57,052 Dominated
AS, yearly 11 15.4 10.6 0.56 52,398 69,380
IRT 27 11 12 16.0 10.2 0.57 55,673 Dominated
55-69 y,
every 2 y
AS, 3 y 16 21.3 14.6 0.96 65,631 100,613
AS, intermediate 16 19.8 13.6 0.98 72,549 Dominated
AS, yearly 18 22.7 15.0 1.00 66,643 106,032
IRT 44 18 18 23.8 14.0 1.03 73,590 Dominated
55-69 y,
yearly
AS, 3 y 19 25.8 17.8 1.63 91,654 Weakly dominated
AS, intermediate 19 24.2 16.2 1.68 103,484 Dominated
AS, yearly 21 28.0 18.4 1.69 91,979 201,719
IRT 53 23 23 29.8 16.9 1.75 103,037 Dominated
Abbreviations: AS, active surveillance; ICER, incremental cost-effectiveness ratio; IRT, immediate radical treatment; LY, life-year; PCM, prostate cancer mortality;
QALY, quality-adjusted life-year.
Effects per 1000 screened men are shown. Costs and effects are discounted at 3%. QALYs were calculated by the multiplication of the loss in utility with the
duration of the phase and the number of men who experienced the event, as predicted by MISCAN (see Supporting Table 4 for additional effects [see online
supporting information]).
a IRT could be either radical prostatectomy or radiation therapy (equal probability). Yearly indicates yearly biopsies, 3 y indicates biopsy every 3 years after the
first year, and intermediate indicates the admission of low- and intermediate-risk patients for AS with yearly biopsies.
b The total cost includes costs for screening, treatment, and palliative therapy, which we assume was given to all men who died of prostate cancer. Net costs
were calculated from the difference between the total costs in a situation without screening and the total costs in a situation with screening. Costs are shown
in millions of 2015 US dollars.
c A policy is classified as dominated if there is another policy that has a lower cost and results in more QALYs gained. Weakly dominated policies are less
effective policies that have a higher cost-effectiveness ratio than the next ranked policy.
d Screening was performed at the ages of 55, 59, 63, and 67 years.
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based on a single cohort,16 and our model of AS assumes
100% referral of low-risk men to AS, whereas in the
United States, this is likely far from 100%.3 These results
may not be applicable to the African American population
because of the higher incidence of the disease30 or to men
with significant comorbidities, who will likely not benefit
from PSA screening.31
Because PSA is not very specific for the detection of
high-risk prostate cancer, many efforts are underway with
the goal of decreasing overdiagnosis and/or improving the
detection of high-risk cancers with genetic markers,32 bio-
markers,33,34 risk calculators,35 panels of many markers,36
and magnetic resonance imaging (MRI)–guided biopsy.37
For instance, genetic tests could be applied before the PSA
test to divide men into different risk categories, and risk-
stratified screening policies could be applied; men at
higher risk would be screened more intensively.32 After an
elevated PSA test, risk calculators35,36 or MRI37 could be
used to decide whether men should go through prostate
biopsy and/or to improve the selection of men for AS.
These developments will likely significantly improve the
efficacy of screening in terms of QALYs gained because
many men will avoid biopsy and a cancer diagnosis.
However, costs in the diagnosis phase could also substan-
tially increase according to MRI usage.
Prostate cancer screening is still a controversial topic.
The 2 major randomized controlled trials of prostate can-
cer screening, ERSPC27 and PLCO,38 showed conflicting
results for the effect of prostate cancer screening on pros-
tate cancer mortality, likely because of the large amount of
screening in the control group of the PLCO trial.39 With
modeling, we can weigh the number of life-years gained,
with the burden experienced by the many men who are
unnecessarily diagnosed and treated, and we can evaluate
whether PSA screening is worthwhile. In this study, we
have found that screening between the ages of 55 and 69
years combined with AS for low-risk men could be cost-
effective at a $100,000 threshold if the screening fre-
quency remains low (quadrennial) and AS is offered to all
low-risk men (Gleason score of 6 and stage T2a or lower).
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